Correction Notice

The following updates were made to Medications in Single-Dose Vials: Implications of Discarded Drugs:

p. 144: The following disclosures were added to Anupam Jena’s biosketch in Appendix D:

Dr. Jena provided compensated expert litigation consulting services in 2020 and 2021 to pharmaceutical companies including Merck, Genentech, Sanofi-Aventis, Janssen, and others through his affiliation with Analysis Group. Prior to his service on the committee, he was a consultant for pharmaceutical companies including Amgen, Eisai, and Otsuka through his affiliation with Precision Health Economics.

p. 146: The following disclosures were added to Gary Lyman’s biosketch in Appendix D:

Dr. Lyman made invited presentations in 2020 regarding the ASCO clinical practice guidelines for complications of cancer chemotherapy, the development of clinical pathways in oncology, and the work of the ASCO taskforce on biosimilars for which he received compensation from Jazz Pharmaceuticals, Merck Sharp & Dohme, Partner Therapeutics, Sandoz, and Seagen.

p. 151: The following paragraphs were added to Appendix D:

Since the release of this report, it was determined that two members of the committee had financial conflicts of interest during the course of the study that had not been fully disclosed.

Dr. Anupum Jena provided compensated expert litigation consulting services in 2020 and 2021 to pharmaceutical companies including Merck, Genentech, Sanofi-Aventis, Janssen, and others through his affiliation with Analysis Group. Although these cases did not directly involve discarded drugs, because the recommendations of the study could be viewed as having a direct impact on the financial interests of some of these companies, the National Academies have concluded that Dr. Jena had a financial conflict of interest during the course of the study.

Dr. Gary Lyman made invited presentations in 2020 regarding the American Society of Clinical Oncology (ASCO) clinical practice guidelines for complications of cancer chemotherapy, the development of clinical pathways in oncology, and the work of the ASCO taskforce on biosimilars for which he received compensation from Jazz Pharmaceuticals, Merck Sharp & Dohme, Partner Therapeutics, Sandoz, and Seagen. Although the topics of these presentations were not directly related to the specific questions addressed by the committee, because the recommendations of the study could be viewed as having a direct impact on the financial interests of some of these companies, the National Academies have concluded that Dr. Lyman had a financial conflict of interest during the course of the study.